KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Taxes: 2016-2020

Historic Change in Taxes for Supernus Pharmaceuticals (SUPN) over the last 5 years, with Sep 2020 value amounting to -$25.1 million.

  • Supernus Pharmaceuticals' Change in Taxes fell 1268.42% to -$25.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$4.9 million, marking a year-over-year decrease of 31.72%. This contributed to the annual value of -$9.9 million for FY2019, which is 178.97% down from last year.
  • Supernus Pharmaceuticals' Change in Taxes amounted to -$25.1 million in Q3 2020, which was down 257.96% from $15.9 million recorded in Q2 2020.
  • In the past 5 years, Supernus Pharmaceuticals' Change in Taxes ranged from a high of $15.9 million in Q2 2020 and a low of -$25.1 million during Q3 2020.
  • Moreover, its 3-year median value for Change in Taxes was $2.1 million (2019), whereas its average is -$1.5 million.
  • Its Change in Taxes has fluctuated over the past 5 years, first spiked by 7,481.82% in 2017, then plummeted by 24,176.12% in 2018.
  • Supernus Pharmaceuticals' Change in Taxes (Quarterly) stood at -$804,000 in 2016, then spiked by 1,275.25% to $9.4 million in 2017, then crashed by 59.48% to $3.8 million in 2018, then crashed by 162.03% to -$2.4 million in 2019, then crashed by 1,268.42% to -$25.1 million in 2020.
  • Its Change in Taxes stands at -$25.1 million for Q3 2020, versus $15.9 million for Q2 2020 and $6.7 million for Q1 2020.